These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 28216072)

  • 81. Long-Term Impact of Belimumab on Health-Related Quality of Life and Fatigue in Patients With Systemic Lupus Erythematosus: Six Years of Treatment.
    Strand V; Berry P; Lin X; Asukai Y; Punwaney R; Ramachandran S
    Arthritis Care Res (Hoboken); 2019 Jun; 71(6):829-838. PubMed ID: 30320964
    [TBL] [Abstract][Full Text] [Related]  

  • 82. B lymphocyte stimulator modulates number and function of endothelial progenitor cells in systemic lupus erythematosus.
    Spinelli FR; Barbati C; Cecarelli F; Morello F; Colasanti T; Vomero M; Massaro L; Orefice V; Alessandri C; Valesini G; Conti F
    Arthritis Res Ther; 2019 Nov; 21(1):245. PubMed ID: 31752963
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Evaluation of belimumab treatment in patients with systemic lupus erythematosus in a clinical practice setting: Results from a 24-month OBSErve study in Argentina.
    Babini A; Cappuccio AM; Caprarulo C; Casado G; Eimon A; Figueredo H; García MA; Magri S; Mannucci P; Perez Rodriguez S; Pons-Estel BA; Velozo EJ; Iglesias-Rodriguez M; Streger G
    Lupus; 2020 Oct; 29(11):1385-1396. PubMed ID: 32791930
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.
    Dooley MA; Houssiau F; Aranow C; D'Cruz DP; Askanase A; Roth DA; Zhong ZJ; Cooper S; Freimuth WW; Ginzler EM;
    Lupus; 2013 Jan; 22(1):63-72. PubMed ID: 23263865
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review.
    Sciascia S; Radin M; Yazdany J; Levy RA; Roccatello D; Dall'Era M; Cuadrado MJ
    Autoimmun Rev; 2017 Mar; 16(3):287-293. PubMed ID: 28147262
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Successful sequential therapy with rituximab and belimumab in patients with active systemic lupus erythematosus: a case series.
    Gualtierotti R; Borghi MO; Gerosa M; Schioppo T; Larghi P; Geginat J; Meroni PL
    Clin Exp Rheumatol; 2018; 36(4):643-647. PubMed ID: 29533753
    [TBL] [Abstract][Full Text] [Related]  

  • 87. [Lupus erythematosus treatment with belimumab in daily practice: Retrospective study of 15 patients].
    Garval E; Pennaforte JL; Jaussaud R; Servettaz A; Bernard P; Reguiai Z
    Ann Dermatol Venereol; 2018 Jan; 145(1):5-12. PubMed ID: 29113694
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Belimumab: targeted therapy for lupus.
    Chugh PK; Kalra BS
    Int J Rheum Dis; 2013 Feb; 16(1):4-13. PubMed ID: 23441766
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Cigarette smoking and disease activity in systemic lupus erythematosus.
    Ghaussy NO; Sibbitt W; Bankhurst AD; Qualls CR
    J Rheumatol; 2003 Jun; 30(6):1215-21. PubMed ID: 12784392
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Assessment of clinical manifestations, disease activity and organ damage in 996 Korean patients with systemic lupus erythematosus: comparison with other Asian populations.
    Joo YB; Bae SC
    Int J Rheum Dis; 2015 Feb; 18(2):117-28. PubMed ID: 25524656
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study.
    Mok CC; Ho LY; Cheung MY; Yu KL; To CH
    Scand J Rheumatol; 2009; 38(2):121-7. PubMed ID: 18991189
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index.
    Kalunian KC; Urowitz MB; Isenberg D; Merrill JT; Petri M; Furie RA; Morgan-Cox MA; Taha R; Watts S; Silk M; Linnik MD
    Rheumatology (Oxford); 2018 Jan; 57(1):125-133. PubMed ID: 29045736
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Management of non-renal non-neurologic persistent lupus activity in real world patients from Argentina.
    Scolnik M; Scaglioni V; Pons-Estel GJ; Soriano ER
    Lupus; 2019 Aug; 28(9):1167-1173. PubMed ID: 31299882
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Performance of systemic lupus erythematosus responder index for detecting clinician-rated responders in patients with active systemic lupus erythematosus.
    Leosuthamas P; Narongroeknawin P; Chaiamnuay S; Asavatanabodee P; Pakchotanon R
    Int J Rheum Dis; 2023 Apr; 26(4):667-672. PubMed ID: 36802112
    [TBL] [Abstract][Full Text] [Related]  

  • 95. The effect of systemic lupus erythematosus (SLE) Disease Activity Score and SLE Disease Activity Index 2000-based remission states in patients with SLE on damage accrual.
    Chitpet P; Chaiamnuay S; Narongroeknawin P; Asavatanabodee P; Leosuthamas P; Pakchotanon R
    Int J Rheum Dis; 2023 Dec; 26(12):2509-2516. PubMed ID: 37875327
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Elevated B lymphocyte stimulator levels are associated with increased damage in an Irish systemic lupus erythematosus cohort.
    McCarthy EM; Lee RZ; Ní Gabhann J; Smith S; Cunnane G; Doran MF; Howard D; O'Connell P; Kearns G; Jefferies CA
    Rheumatology (Oxford); 2013 Jul; 52(7):1279-84. PubMed ID: 23479724
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Comparative efficacy and safety of intravenous or subcutaneous belimumab in combination with standard therapy in patients with active systemic lupus erythematosus: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Song GG
    Lupus; 2018 Jan; 27(1):112-119. PubMed ID: 28592201
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Predictors of Organ Damage Progression and Effect on Health-related Quality of Life in Systemic Lupus Erythematosus.
    Legge A; Doucette S; Hanly JG
    J Rheumatol; 2016 Jun; 43(6):1050-6. PubMed ID: 27084911
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Belimumab: a guide to its use in systemic lupus erythematosus.
    Scott LJ; Burness CB; McCormack PL
    BioDrugs; 2012 Jun; 26(3):195-9. PubMed ID: 22428610
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Update on belimumab for the management of systemic lupus erythematosus.
    Lutalo PM; D'Cruz DP
    Expert Opin Biol Ther; 2014 Nov; 14(11):1701-8. PubMed ID: 25303323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.